Skip to Main Content

Paper Details

Combined inhibition of XIAP and BCL2 drives maximal therapeutic efficacy in genetically diverse aggressive acute myeloid leukemia.
Nat Cancer
13
2021
AML, AURKB, BCL2, MCL1, PDXs, XIAP, acute myeloid leukemia, genetic aberrations, human, patient, patient-derived xenografts
Author NameAffiliation
Jordan A RamilowskiRIKEN Center for Integrative Medical Sciences
Jessica SeverinRIKEN Center for Integrative Medical Sciences
Ri-Ichiroh ManabeRIKEN Center for Integrative Medical Sciences
Yasushi OkazakiRIKEN Center for Integrative Medical Sciences
Yasushi OkazakiRIKEN Center for Integrative Medical Sciences
Osamu OharaRIKEN Center for Integrative Medical Sciences
Leonard D Shultz
Leonard D Shultz
Dave S B HoonRIKEN Center for Integrative Medical Sciences
Dave S B HoonRIKEN Center for Integrative Medical Sciences
  • 1 - 10

Datasets

Release 1.2